Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
Status:
Completed
Trial end date:
2019-11-22
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 (monthly
TEV-48125 225 mg and TEV-48125 675 mg once over a period of 3 months) compared with placebo
for preventive treatment in Episodic Migraine patients